Multi-Specific Antibodies for Cancer Immunotherapy

Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study

(2013) L G Lum et al.   BONE MARROW TRANSPLANTATION

Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results

(2013) R Schoffelen et al.   BRITISH JOURNAL OF CANCER

Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab

(2013) D. Goere et al.   CANCER RESEARCH

Antitumor Immunity: Easy as 1, 2, 3 with Monoclonal Bispecific Trifunctional Antibodies?

(2013) J. Maher et al.   CANCER RESEARCH

Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors

(2013) Alessandro Satta et al.   Future Oncology

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients

(2013) Douglas A. Rubinson et al.   INVESTIGATIONAL NEW DRUGS

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

(2013) Raymund Buhmann et al.   Journal of Translational Medicine

Bispecific small molecule-antibody conjugate targeting prostate cancer

(2013) C. H. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting

(2013) Djordje Atanackovic et al.   Human Vaccines & Immunotherapeutics

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer

(2012) Philippe Fournier et al.   BIODRUGS

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

(2012) P. Gupta et al.   BLOOD

T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16

(2012) Lisa M. Pörtner et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation

(2012) S. Huang et al.   CANCER RESEARCH

RECRUIT-TandAbs®: harnessing the immune system to kill cancer cells

(2012) Fionnuala McAleese et al.   Future Oncology

Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

(2012) P.-Y. Salaun et al.   JOURNAL OF NUCLEAR MEDICINE

Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

(2012) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

(2012) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer

(2012) Fausto Petrelli et al.   Targeted Oncology

Cancer stromal targeting (CAST) therapy

(2011) Yasuhiro Matsumura   ADVANCED DRUG DELIVERY REVIEWS

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

(2011) P. A. Moore et al.   BLOOD

Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)

(2011) M. Jager et al.   CANCER RESEARCH

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

(2011) S. I. Rudnick et al.   CANCER RESEARCH

EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells

(2011) M. Cioffi et al.   CLINICAL CANCER RESEARCH

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group

(2011) K. Baumann et al.   GYNECOLOGIC ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

(2011) Jianying Dong et al.   mAbs

A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting

(2011) Ingo Schubert et al.   mAbs

Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma

(2011) R. D. Jachimowicz et al.   MOLECULAR CANCER THERAPEUTICS

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias

(2010) P. Gupta et al.   BLOOD

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

(2010) Markus Kügler et al.   BRITISH JOURNAL OF HAEMATOLOGY

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

(2010) Jennifer S. Michaelson et al.   mAbs

Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells

(2010) Ines Herrmann et al.   PLoS One

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody

(2009) T Osada et al.   BRITISH JOURNAL OF CANCER

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy

(2009) Daniel A. Vallera et al.   LEUKEMIA RESEARCH

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

(2008) R Buhmann et al.   BONE MARROW TRANSPLANTATION

Ertumaxomab: a trifunctional antibody for breast cancer treatment

(2008) Philipp Kiewe et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells

(2008) Christian Kellner et al.   JOURNAL OF IMMUNOTHERAPY

A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells

(2008) T Otz et al.   LEUKEMIA

Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells

(2008) Sandrine d’Argouges et al.   LEUKEMIA RESEARCH

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE